Literature DB >> 35450372

Discovery of SHR2415, a Novel Pyrrole-Fused Urea Scaffold ERK1/2 Inhibitor.

Xin Li1, Ping Dong1, Ting Zhang1, Guodong Cai1, Yang Chen1, Huaide Dong1, Fang Yang1, Lei Zhang1, Yuchang Mao1, Jun Feng1, Chang Bai1, Feng He1, Weikang Tao1.   

Abstract

ERK1/2 kinase is a key downstream node of the RAS-RAF-MEK-ERK signaling pathway. A highly potent and selective ERK1/2 inhibitor is a promising option for cancer treatment that will provide a potential solution for overcoming drug resistance. Herein we designed and synthesized a novel scaffold featuring a pyrrole-fused urea template. The lead compound, SHR2415, was shown to be a highly potent ERK1/2 inhibitor that exhibited high cell potency based on the Colo205 assay. In addition, SHR2415 displayed favorable PK profiles across species as well as robust in vivo efficacy in a mouse Colo205 xenograft model.
© 2022 American Chemical Society.

Entities:  

Year:  2022        PMID: 35450372      PMCID: PMC9014502          DOI: 10.1021/acsmedchemlett.2c00029

Source DB:  PubMed          Journal:  ACS Med Chem Lett        ISSN: 1948-5875            Impact factor:   4.632


  19 in total

1.  Dabrafenib plus trametinib in patients with previously untreated BRAFV600E-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial.

Authors:  David Planchard; Egbert F Smit; Harry J M Groen; Julien Mazieres; Benjamin Besse; Åslaug Helland; Vanessa Giannone; Anthony M D'Amelio; Pingkuan Zhang; Bijoyesh Mookerjee; Bruce E Johnson
Journal:  Lancet Oncol       Date:  2017-09-11       Impact factor: 41.316

2.  Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function.

Authors:  Andrea Boni; Alexandria P Cogdill; Ping Dang; Durga Udayakumar; Ching-Ni Jenny Njauw; Callum M Sloss; Cristina R Ferrone; Keith T Flaherty; Donald P Lawrence; David E Fisher; Hensin Tsao; Jennifer A Wargo
Journal:  Cancer Res       Date:  2010-06-15       Impact factor: 12.701

3.  Characteristics of pyrexia in BRAFV600E/K metastatic melanoma patients treated with combined dabrafenib and trametinib in a phase I/II clinical trial.

Authors:  A M Menzies; M T Ashworth; S Swann; R F Kefford; K Flaherty; J Weber; J R Infante; K B Kim; R Gonzalez; O Hamid; L Schuchter; J Cebon; J A Sosman; S Little; P Sun; G Aktan; D Ouellet; F Jin; G V Long; A Daud
Journal:  Ann Oncol       Date:  2014-11-18       Impact factor: 32.976

4.  Efficacy of a Covalent ERK1/2 Inhibitor, CC-90003, in KRAS-Mutant Cancer Models Reveals Novel Mechanisms of Response and Resistance.

Authors:  Ida Aronchik; Yumin Dai; Matt Labenski; Carmen Barnes; Terri Jones; Lixin Qiao; Lisa Beebe; Mehnaz Malek; Winfried Elis; Tao Shi; Konstantinos Mavrommatis; Gordon L Bray; Ellen H Filvaroff
Journal:  Mol Cancer Res       Date:  2018-10-01       Impact factor: 5.852

Review 5.  Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer.

Authors:  P J Roberts; C J Der
Journal:  Oncogene       Date:  2007-05-14       Impact factor: 9.867

6.  Discovery of (S)-1-(1-(4-Chloro-3-fluorophenyl)-2-hydroxyethyl)-4-(2-((1-methyl-1H-pyrazol-5-yl)amino)pyrimidin-4-yl)pyridin-2(1H)-one (GDC-0994), an Extracellular Signal-Regulated Kinase 1/2 (ERK1/2) Inhibitor in Early Clinical Development.

Authors:  James F Blake; Michael Burkard; Jocelyn Chan; Huifen Chen; Kang-Jye Chou; Dolores Diaz; Danette A Dudley; John J Gaudino; Stephen E Gould; Jonas Grina; Thomas Hunsaker; Lichuan Liu; Matthew Martinson; David Moreno; Lars Mueller; Christine Orr; Patricia Pacheco; Ann Qin; Kevin Rasor; Li Ren; Kirk Robarge; Sheerin Shahidi-Latham; Jeffrey Stults; Francis Sullivan; Weiru Wang; Jianping Yin; Aihe Zhou; Marcia Belvin; Mark Merchant; John Moffat; Jacob B Schwarz
Journal:  J Med Chem       Date:  2016-06-07       Impact factor: 7.446

7.  Discovery of a Potent and Selective Oral Inhibitor of ERK1/2 (AZD0364) That Is Efficacious in Both Monotherapy and Combination Therapy in Models of Nonsmall Cell Lung Cancer (NSCLC).

Authors:  Richard A Ward; Mark J Anderton; Paul Bethel; Jason Breed; Calum Cook; Emma J Davies; Andrew Dobson; Zhiqiang Dong; Gary Fairley; Paul Farrington; Lyman Feron; Vikki Flemington; Francis D Gibbons; Mark A Graham; Ryan Greenwood; Lyndsey Hanson; Philip Hopcroft; Rachel Howells; Julian Hudson; Michael James; Clifford D Jones; Christopher R Jones; Yongchao Li; Scott Lamont; Richard Lewis; Nicola Lindsay; James McCabe; Thomas McGuire; Philip Rawlins; Karen Roberts; Linda Sandin; Iain Simpson; Steve Swallow; Jia Tang; Gary Tomkinson; Michael Tonge; Zhenhua Wang; Baochang Zhai
Journal:  J Med Chem       Date:  2019-11-25       Impact factor: 7.446

Review 8.  Mechanisms of acquired resistance to ERK1/2 pathway inhibitors.

Authors:  A S Little; P D Smith; S J Cook
Journal:  Oncogene       Date:  2012-05-07       Impact factor: 9.867

Review 9.  ERK1/2 MAP kinases: structure, function, and regulation.

Authors:  Robert Roskoski
Journal:  Pharmacol Res       Date:  2012-04-27       Impact factor: 7.658

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.